WO2018126522A1 - Médicament antiviral injectable intraoculaire à libération prolongée, son procédé de fabrication et son application - Google Patents
Médicament antiviral injectable intraoculaire à libération prolongée, son procédé de fabrication et son application Download PDFInfo
- Publication number
- WO2018126522A1 WO2018126522A1 PCT/CN2017/074975 CN2017074975W WO2018126522A1 WO 2018126522 A1 WO2018126522 A1 WO 2018126522A1 CN 2017074975 W CN2017074975 W CN 2017074975W WO 2018126522 A1 WO2018126522 A1 WO 2018126522A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- salt
- foscarnet
- microcrystal
- phosphonic acid
- phosphonoformate
- Prior art date
Links
- 238000013268 sustained release Methods 0.000 title claims abstract description 47
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 46
- 239000003443 antiviral agent Substances 0.000 title claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical class OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 claims abstract description 131
- 150000003839 salts Chemical class 0.000 claims abstract description 85
- 229960005102 foscarnet Drugs 0.000 claims abstract description 62
- 239000013081 microcrystal Substances 0.000 claims abstract description 41
- 239000003814 drug Substances 0.000 claims abstract description 36
- 229910052751 metal Inorganic materials 0.000 claims abstract description 25
- 239000002184 metal Substances 0.000 claims abstract description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000011734 sodium Substances 0.000 claims description 22
- 229910052708 sodium Inorganic materials 0.000 claims description 22
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 21
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 14
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 239000013078 crystal Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 208000017442 Retinal disease Diseases 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 230000003612 virological effect Effects 0.000 claims description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- 239000011575 calcium Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 239000005819 Potassium phosphonate Substances 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- YXXXKCDYKKSZHL-UHFFFAOYSA-M dipotassium;dioxido(oxo)phosphanium Chemical compound [K+].[K+].[O-][P+]([O-])=O YXXXKCDYKKSZHL-UHFFFAOYSA-M 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 235000019253 formic acid Nutrition 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 33
- 238000002347 injection Methods 0.000 abstract description 21
- 239000007924 injection Substances 0.000 abstract description 21
- 241000283973 Oryctolagus cuniculus Species 0.000 abstract description 17
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 238000013270 controlled release Methods 0.000 abstract description 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- BWGBIGLMQJPOEE-UHFFFAOYSA-M sodium;phosphonoformate Chemical compound [Na+].OP(O)(=O)C([O-])=O BWGBIGLMQJPOEE-UHFFFAOYSA-M 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 8
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 5
- YPPQYORGOMWNMX-UHFFFAOYSA-L sodium phosphonate pentahydrate Chemical compound [Na+].[Na+].[O-]P([O-])=O YPPQYORGOMWNMX-UHFFFAOYSA-L 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 4
- 238000002441 X-ray diffraction Methods 0.000 description 3
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 3
- 229960002963 ganciclovir Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- -1 phosphofuric acid Chemical compound 0.000 description 3
- 238000001878 scanning electron micrograph Methods 0.000 description 3
- 238000004626 scanning electron microscopy Methods 0.000 description 3
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 210000001742 aqueous humor Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000011587 new zealand white rabbit Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- 238000000918 plasma mass spectrometry Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000004127 vitreous body Anatomy 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 208000004142 Acute Retinal Necrosis Syndrome Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 239000000112 cooling gas Substances 0.000 description 1
- 230000005574 cross-species transmission Effects 0.000 description 1
- 208000001763 cytomegalovirus retinitis Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 208000013441 ocular lesion Diseases 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- the invention belongs to the field of medicines, and particularly relates to an anti-virus sustained-release medicine which can be used for intraocular injection, a preparation method and application thereof.
- Viral retinal disease is an ocular lesion with a high risk of visual impairment and blindness, and is diverse in many diseases, including cytomegalovirus retinitis, acute retinal necrosis, and progressive outer retinopathy.
- the incidence of viral retinal diseases has increased in recent years due to the combination of an aging population, the spread of AIDS, the use of new immunosuppressants, unhealthy lifestyle habits, and increased stress.
- Intravitreal injection of antiviral drugs is an important way to treat viral retinal diseases clinically.
- Injectable drugs include sodium foscarnet and ganciclovir.
- the half-life of sodium foscarnet in the eye is very short, and after 12 hours, the concentration of sodium foscarnet in the eye drops by more than half. After a single injection of sodium foscarnet, the effective drug concentration in the eye does not exceed 3 days. Therefore, clinically, patients with viral retinal diseases often require frequent intraocular drug injections, which greatly increases the economic burden on patients and families, and also makes the overall therapeutic effect of viral retinal diseases poor.
- the FDA approved a sustained release device for ganciclovir but the device has the disadvantage of requiring re-surgery after the drug is released.
- the upper limit of the injection volume is 0.1 mL, and considering that the solid content of the injection suspension cannot be too high, which requires that the sustained release system must have a high drug loading amount.
- the dosage of sodium foscarnet is much higher than that of ganciclovir.
- the long-term sustained release in the eye requires a specially designed system with a drug loading of nearly 100%, which is technically challenging.
- intravitreal injection The needle model is 27G or finer, and its inner diameter is only 210 ⁇ m, which requires the particles of the sustained release system to have suitable size and is not easy to aggregate.
- the intraocular environment requires strict sterile materials, and the materials used for injection must pass through. Strictly disinfected.
- One of the objects of the present invention is to provide a phosphonic acid insoluble salt microcrystal.
- the phosphoric acid insoluble salt is a polyvalent metal salt of foscarnet, and the polyvalent metal may be selected from at least one of calcium, magnesium, zinc and aluminum. .
- the phosphonium insoluble salt microcrystals have a diameter ranging from 0.1 to 100 ⁇ m, preferably from 1 to 50 ⁇ m.
- the foscarnet poorly soluble salt microcrystals may comprise bound water.
- the foscarnet poorly soluble salt microcrystals provided by the present invention are prepared according to the method comprising the following steps:
- the monovalent metal salt of the foscarnet and the soluble salt of the polyvalent metal are reacted in water to obtain a system containing the micron crystal of the phosphonium insoluble salt.
- the monovalent metal salt of foscarnet may specifically be sodium foscarnet or potassium phosphonate.
- the molar ratio of the monovalent metal salt of foscarnet to the soluble salt of the polyvalent metal is from 1:1 to 1:10.
- the reaction time is from 0.1 to 24 hours, specifically 1 hour.
- the reaction is carried out with stirring.
- the monovalent metal salt of foscarnet is added as an aqueous solution; the soluble salt of the polyvalent metal is also added as an aqueous solution.
- the aqueous solution of the monovalent metal salt of foscarnet has a concentration of 0.1 to 500 mg/mL, specifically 1 to 10 mg/mL.
- the concentration of the aqueous solution of the soluble salt of the polyvalent metal is from 0.1 to 500 mg/mL, specifically from 1 to 10 mg/mL.
- the method further includes the operation of isolating the phosphonic acid insoluble salt microcrystals from the obtained system containing the phosphonic acid insoluble salt microcrystals.
- the operation is: the system containing the phosphonic acid insoluble salt microcrystals is allowed to stand, filtered, the solid is collected, washed, and the suspension is lyophilized to obtain a phosphonic acid insoluble salt microcrystal.
- Another object of the present invention is to provide an antiviral drug having a sustained release effect which can be injected intraocularly.
- the antiviral drug having a sustained release effect which can be administered intraocularly according to the present invention is the above-mentioned phosphonic acid insoluble salt microcrystal or a suspension containing the above-mentioned phosphonium insoluble salt microcrystal.
- the invention aims at the special requirement of intraocular injection and controlled release, and designs and develops a phosphonium insoluble salt microcrystalline sustained release system, which can be loaded with a nominal amount of more than 100% relative to the sodium foscarnet.
- the sustained release of the drug in the vitreous cavity is achieved by preparing an injectable phosphofuric acid insoluble salt microcrystal using its dissolution equilibrium.
- the foscarnet insoluble salt microcrystalline sustained-release drug prepared by the invention can well solve the problem that the sodium foscarnet needs frequent injections, and the insoluble salt of the foscarnet should be used as a glass. Injectable slow release techniques for antiviral drugs in body cavity are used.
- FIG. 1 is a flow chart showing the preparation of a phosphonium insoluble salt microcrystalline sustained-release drug prepared by the present invention.
- FIG. 2 is a scanning electron micrograph of a phosphonium insoluble salt microcrystalline sustained-release drug prepared according to the present invention.
- Figure 3 is an X-ray diffraction pattern of the foscarnet insoluble salt microcrystalline sustained release drug and the raw material sodium foscarnet prepared according to the present invention.
- Fig. 4 is a view showing the presence of a phosphonium insoluble salt microcrystalline sustained-release drug prepared by the present invention in rabbit eyes and the health condition of a rabbit eye in an animal experiment.
- Figure 5 is a scanning electron micrograph of a foscarnet insoluble salt microcrystalline sustained release drug taken from rabbit eyes in an animal experiment.
- Figure 6 is a graph showing changes in the concentration of foscarnet in the vitreous and aqueous humor of rabbit eyes in an animal experiment.
- a phosphonic acid insoluble salt microcrystal was prepared.
- a 6 mg/mL sodium phosphonate sodium aqueous solution and a 6 mg/mL calcium chloride solution were prepared, and the two solutions were mixed and reacted in a volume ratio of 1:1 to obtain a product b.
- Fig. 2 (a), (b) and (c) are scanning electron micrographs of the prepared micronized crystals of foscarnet insoluble salts, a, b and c, respectively, and the average sizes thereof are estimated to be 10 ⁇ m, 60 ⁇ m and 100 ⁇ m, respectively.
- the crystals are grown in the radial direction from the center to form a micron-sized spherical crystal.
- X-ray diffraction characterization phosphonic acid insoluble salt microcrystal freeze-dried powder and sodium foscarnet standard They were respectively ground with a mortar, sieved with a 100 mesh sieve, and characterized by an X-ray diffractometer. The test conditions were: 2 ° 2 ⁇ / min, step size 0.02 ° 2 ⁇ , using Cu K ⁇ ray. The experimental results are shown in Figure 3.
- the size of the phosphonium insoluble salt microcrystalline sustained release drug can be controlled by adjusting the initial concentration of the sodium foscarnet solution and the calcium chloride solution and the mixing volume ratio.
- the crystallinity of the sample is close to 100%, and its crystal structure is different from that of the raw material sodium foscarnet.
- Determination of the content of Ca, Na and P elements foscarnet insoluble salts extended release pharmaceutical micron crystals utilizing plasma mass spectrometry (ICP-MS), whereby molecular structure was confirmed foscarnet insoluble salts of Ca 3 (CO 5 P) 2 or write Ca 3 (pfa) 2 .
- Table 1 is the equilibrium solubility value of the foscarnet insoluble salt microcrystals (product a) prepared in Example 1 under different conditions.
- micron crystal of the foscarnet insoluble salt microcrystal can be prepared by directly mixing the sodium phosphonate solution with the calcium chloride solution, and the insoluble intravitate microcrystal can satisfy the intraocular injection (the particle size is below 100 microns). And have the basic requirements of anti-viral drugs with sustained release effect.
- Example 3 Intraocular sustained release experiment of micron crystals of foscarnet insoluble salt microcrystals
- the animal experiment steps are as follows:
- Fig. 4 is a view showing the presence of a phosphonium insoluble salt microcrystalline sustained-release drug prepared by the present invention in rabbit eyes and the health condition of a rabbit eye in an animal experiment.
- the foscarnet insoluble salt microcrystalline sustained-release drug prepared by the invention can be stably and sustainedly released in the vitreous cavity of the rabbit eye, and the concentration of the phosphonate root in the vitreous cavity is maintained above the effective therapeutic concentration of the sodium foscarnet, and the sustained release period is long. After 12 weeks, the rabbit eyes were in good health after 12 weeks. Therefore, it has been proved by animal experiments that the foscarnet insoluble salt microcrystalline sustained-release drug prepared by the invention can well solve the problem that the sodium foscarnet needs frequent injections, and the insoluble salt of the foscarnet should be used as a glass. Injectable slow release techniques for antiviral drugs in body cavity are used.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention concerne un médicament antiviral injectable intraoculaire à libération prolongée, son procédé de fabrication et son application. Le médicament antiviral est un microcristal de sel de phosphonoformate insoluble. Le sel de phosphonoformate insoluble est un sel métallique multivalent d'acide phosphonoformique. Le procédé de fabrication selon l'invention comprend : la mise en réaction d'un sel métallique monovalent d'acide phosphonoformique avec un sel métallique multivalent soluble dans l'eau ; et l'obtention d'un système contenant le microcristal de sel de phosphonoformate insoluble. Un système de libération prolongée de microcristaux du sel de phosphonoformate insoluble est conçu et développé pour répondre aux besoins spéciaux d'une injection intraoculaire à libération prolongée et contrôlée. La charge nominale du médicament du système est supérieure à 100 %. Le médicament antiviral à libération prolongée du sel de phosphonoformate insoluble peut être libéré de manière durable et stable dans la cavité vitréenne d'un œil de lapin. La concentration vitreuse du phosphonoformate reste en continu supérieure à une concentration thérapeutique efficace du phosphonoformate de sodium. Le médicament antiviral a une période de libération prolongée allant jusqu'à 12 semaines et n'induit pas de réactions toxiques ou inflammatoires significatives. Le sel de phosphonoformate insoluble peut être utilisé en tant que médicament antiviral approprié pour une technologie d'injection intravitréenne à libération prolongée.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710006803.1 | 2017-01-05 | ||
CN201710006803.1A CN108276440B (zh) | 2017-01-05 | 2017-01-05 | 一种可眼内注射使用的抗病毒缓释药物及其制备方法与应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018126522A1 true WO2018126522A1 (fr) | 2018-07-12 |
Family
ID=62788878
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2017/074975 WO2018126522A1 (fr) | 2017-01-05 | 2017-02-27 | Médicament antiviral injectable intraoculaire à libération prolongée, son procédé de fabrication et son application |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN108276440B (fr) |
WO (1) | WO2018126522A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111467355B (zh) * | 2020-04-07 | 2021-04-23 | 中国科学院深圳先进技术研究院 | 膦甲酸钠在制备预防和治疗冠状病毒的药物中的应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1433764A (zh) * | 2003-02-28 | 2003-08-06 | 蔡惠明 | 膦甲酸钠凝胶制剂及其制备方法 |
CN101564374A (zh) * | 2008-04-25 | 2009-10-28 | 北京和润创新医药科技发展有限公司 | 一种药物眼用即型凝胶 |
CN103126981A (zh) * | 2013-03-05 | 2013-06-05 | 宁夏康亚药业有限公司 | 膦甲酸钠滴眼液及其制备方法 |
DE102012103717A1 (de) * | 2012-04-27 | 2013-11-14 | Westfälische Wilhelms-Universität Münster | Arzneimittel zur Behandlung von Tumorerkrankungen |
CN104906587A (zh) * | 2015-05-15 | 2015-09-16 | 青岛大学 | 一种膦甲酸钠眼玻璃体腔内缓释药物 |
-
2017
- 2017-01-05 CN CN201710006803.1A patent/CN108276440B/zh active Active
- 2017-02-27 WO PCT/CN2017/074975 patent/WO2018126522A1/fr active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1433764A (zh) * | 2003-02-28 | 2003-08-06 | 蔡惠明 | 膦甲酸钠凝胶制剂及其制备方法 |
CN101564374A (zh) * | 2008-04-25 | 2009-10-28 | 北京和润创新医药科技发展有限公司 | 一种药物眼用即型凝胶 |
DE102012103717A1 (de) * | 2012-04-27 | 2013-11-14 | Westfälische Wilhelms-Universität Münster | Arzneimittel zur Behandlung von Tumorerkrankungen |
CN103126981A (zh) * | 2013-03-05 | 2013-06-05 | 宁夏康亚药业有限公司 | 膦甲酸钠滴眼液及其制备方法 |
CN104906587A (zh) * | 2015-05-15 | 2015-09-16 | 青岛大学 | 一种膦甲酸钠眼玻璃体腔内缓释药物 |
Non-Patent Citations (1)
Title |
---|
SUN, YULING ET AL.: "Foscarnet Calcium Microcrystals as the Intravitreal Drug Depot", CHEM. COMMUN., vol. 53, 13 April 2017 (2017-04-13), pages 5139 - 5142, XP055511401 * |
Also Published As
Publication number | Publication date |
---|---|
CN108276440B (zh) | 2019-07-02 |
CN108276440A (zh) | 2018-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6938425B2 (ja) | 炭酸ランタン水酸化物、ランタンオキシカルボネートならびにその製造および使用方法 | |
Nayak et al. | Ionotropically-gelled mucoadhesive beads for oral metformin HCl delivery: Formulation, optimization and antidiabetic evaluation | |
US20080317807A1 (en) | Strontium fortified calcium nano-and microparticle compositions and methods of making and using thereof | |
CN104350063A (zh) | 疏水性治疗剂的制剂、其制备方法及应用 | |
KR20050089961A (ko) | 유기 폴리머 물질과 결합된 무기 입자들을 포함하고 고형의망상형 매트릭스를 형성하는 약학적 부형제, 조성물, 그의제조 및 용도 | |
US20170105937A1 (en) | Olaparib co-precipitate and preparation method thereof | |
WO2019218409A1 (fr) | Microsphère à libération prolongée d'aripiprazole et son procédé de préparation | |
UA117465C2 (uk) | Продукт cпівмікронізації, який включає ацетат уліпристалу | |
CN106397249A (zh) | 一种高稳定性lcz696结晶粉末及其制备方法 | |
WO2015003479A2 (fr) | Pastille solide administrée par voie orale pour nourrissons et enfants et procédé de préparation | |
CN108938572A (zh) | 一种含有恩替卡韦的长效注射微球及其制备方法 | |
WO2018126522A1 (fr) | Médicament antiviral injectable intraoculaire à libération prolongée, son procédé de fabrication et son application | |
CA2930055C (fr) | Formes de dosage pharmaceutique comprenant un inhibiteur de proteine kinase | |
CN109793715B (zh) | 一种阿哌沙班口服固体制剂及其制备方法 | |
CN104771375B (zh) | 一种盐酸决奈达隆片剂及其制备方法 | |
WO2023016565A1 (fr) | Suspension de microsphères, formulation de microparticules et procédé de préparation de celles-ci | |
CN107184555B (zh) | 一种盐酸丙卡特罗颗粒剂 | |
CN108864069A (zh) | 一种利伐沙班微粒及其制备方法与应用 | |
CA2567916C (fr) | Methode de production d'antibiotiques et de particules antibiotiques et utilisation de ceux-ci | |
CN108057031B (zh) | 预防手术后异位骨化的缓释吲哚美辛纳米颗粒及其注射剂 | |
WO2011016436A1 (fr) | Procédé de production dune composition lyophilisée contenant des particules dacide polylactique | |
CN109925293B (zh) | 依普利酮口服固体制剂及其制备方法 | |
WO2024113533A1 (fr) | Composition pharmaceutique injectable, procédé de préparation associé et son utilisation | |
Nixon et al. | The effect of pH on the release characteristics of thiabendazole microcapsules | |
CN108066298A (zh) | 一种泊马度胺分散片及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17890141 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17890141 Country of ref document: EP Kind code of ref document: A1 |